newsfilter
← Latest News
Business Wire·

TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

TLSI
  • TriSalus Life Sciences announced the resignation of Dr. Arjun "JJ" Desai from its Board of Directors, effective after his tenure since August 2023.
  • Michael P. Stansky was appointed to the Board of Directors effective February 4, 2026.
  • Mr. Stansky possesses 40 years of investment management & healthcare experience, most recently serving as a Managing Director at Tudor Investment Corporation.
  • His prior roles include analyst & portfolio manager at Wellington Management Company, & he currently serves on the boards of Insightec & Momentis Surgical.
  • Mr. Stansky holds a B.A. in Accounting from the University of Massachusetts, an M.B.A. from Harvard Business School, & is a Certified Public Accountant & Chartered Financial Analyst.
  • Chairman Mats Wahlstrom thanked Dr. Desai for his leadership during a critical development period & welcomed Mr. Stansky for his expertise in capital markets & governance.
  • TriSalus is an oncology-focused company utilizing its proprietary Pressure-Enabled Drug Delivery (PEDD) technology to improve outcomes for patients with solid tumors.
  • The company has three FDA-cleared devices: the TriNav Infusion System, TriNav Infusion System LV, & the Pancreatic Retrograde Venous Infusion System.
  • TriSalus is developing nelitolimod, an investigational immunotherapeutic candidate targeting TLR9 to address immunosuppressive tumor environments.
  • The company is in the final stages of data completion for phase 1 clinical trials & plans to explore partnership opportunities for development.